| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/26/2023 | 123.33% | HC Wainwright & Co. | → $9 | Initiates Coverage On | → Buy |
| 03/28/2022 | 24.07% | EF Hutton | → $5 | Initiates Coverage On | → Buy |
What is the target price for TC BioPharm (Holdings) (TCBP)?
The latest price target for TC BioPharm (Holdings) (NASDAQ: TCBP) was reported by HC Wainwright & Co. on January 26, 2023. The analyst firm set a price target for $9.00 expecting TCBP to rise to within 12 months (a possible 123.33% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for TC BioPharm (Holdings) (TCBP)?
The latest analyst rating for TC BioPharm (Holdings) (NASDAQ: TCBP) was provided by HC Wainwright & Co., and TC BioPharm (Holdings) initiated their buy rating.
When is the next analyst rating going to be posted or updated for TC BioPharm (Holdings) (TCBP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TC BioPharm (Holdings), and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TC BioPharm (Holdings) was filed on January 26, 2023 so you should expect the next rating to be made available sometime around January 26, 2024.
Is the Analyst Rating TC BioPharm (Holdings) (TCBP) correct?
While ratings are subjective and will change, the latest TC BioPharm (Holdings) (TCBP) rating was a initiated with a price target of $0.00 to $9.00. The current price TC BioPharm (Holdings) (TCBP) is trading at is $4.03, which is within the analyst's predicted range.